{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:11Z","timestamp":1792723091445,"version":"4.5.0"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.jvca.2026.09.050","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:48:26Z","timestamp":1790725706000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Cardiovascular Pharmacotherapy. XI: Sotatercept in Pulmonary Arterial Hypertension"],"prefix":"10.1053","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2026.09.050_bib0001","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0002","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/rccm.202302-0327SO","article-title":"Pulmonary hypertension: A contemporary review","volume":"208","author":"Johnson","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0003","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1164\/rccm.202405-0914SO","article-title":"Contemporary treatment of pulmonary arterial hypertension: A U.S. perspective","volume":"210","author":"Sahay","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01095-2024","article-title":"Pathology and pathobiology of pulmonary hypertension: Current insights and future directions","volume":"64","author":"Guignabert","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41569-024-01064-4","article-title":"Mechanisms and treatment of pulmonary arterial hypertension","volume":"22","author":"Ghofrani","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0006","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.126.079274","article-title":"Transforming pulmonary arterial hypertension: Key milestones and future perspectives","volume":"154","author":"Humbert","year":"2026","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.09.050_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70353","article-title":"Activin signaling inhibitors in pulmonary hypertension: A state-of-the-art review","volume":"16","author":"Rajagopal","year":"2026","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0008","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/ijms27020767","article-title":"Sotatercept in pulmonary arterial hypertension: Molecular mechanisms, clinical evidence, and emerging role in reverse remodeling","volume":"27","author":"Tilea","year":"2026","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.jvca.2026.09.050_bib0009","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1164\/rccm.201806-1160ST","article-title":"Assessment of right ventricular function in the research setting: Knowledge gaps and pathways forward. An official American Thoracic Society research statement","volume":"198","author":"Lahm","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02334-2021","article-title":"The physiological basis of pulmonary arterial hypertension","volume":"59","author":"Naeije","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0011","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jacc.2016.10.047","article-title":"The relationship between the right ventricle and its load in pulmonary hypertension","volume":"69","author":"Noordergraaf","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0012","article-title":"Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: An update","volume":"53","author":"Noordergraaf","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0013","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0014","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2022.05.038","article-title":"Clinical characteristics and transplant-free survival across the spectrum of pulmonary vascular disease","volume":"80","author":"Hemnes","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0017","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/CIRCRESAHA.122.320084","article-title":"New mutations and pathogenesis of pulmonary hypertension: Progress and puzzles in disease pathogenesis","volume":"130","author":"Aldred","year":"2022","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.09.050_bib0018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCRESAHA.113.301141","article-title":"Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension","volume":"115","author":"Rabinovitch","year":"2014","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.09.050_bib0019","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/ars.2020.8169","article-title":"Endothelial-to-mesenchymal transition in pulmonary arterial hypertension","volume":"34","author":"Gorelova","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"10.1053\/j.jvca.2026.09.050_bib0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03957-2020","article-title":"Endothelial cells in the pathogenesis of pulmonary arterial hypertension","volume":"58","author":"Evans","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0021","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0183-2023","article-title":"The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: From PDE5 to soluble guanylate cyclase","volume":"33","author":"Benza","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1053\/j.jvca.2026.09.050_bib0022","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1053\/j.jvca.2026.02.035","article-title":"Advances in cardiovascular pharmacotherapy. VII. Soluble guanylate cyclase stimulators in pulmonary hypertension and heart failure","volume":"40","author":"Pagel","year":"2026","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.09.050_bib0023","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1056\/NEJMct0904473","article-title":"Phoshodiesterase type 5 inhibitors in pulmonary arterial hypertension","volume":"361","author":"Archer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0024","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0025","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0026","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0027","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0028","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01830-2024","article-title":"Drugs targeting novel pathways in pulmonary arterial hypertension","volume":"66","author":"Sitbon","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0029","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.tibs.2015.03.012","article-title":"Structural determinants of Smad function in TGF-b signaling","volume":"40","author":"Macias","year":"2015","journal-title":"Trends Biochem Sci"},{"key":"10.1053\/j.jvca.2026.09.050_bib0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0092-8674(00)81696-7","article-title":"Smads: Transcriptional activators of TGF-beta responses","volume":"95","author":"Derynck","year":"1998","journal-title":"Cell"},{"key":"10.1053\/j.jvca.2026.09.050_bib0031","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1101\/gad.1350705","article-title":"Smad transcription factors","volume":"19","author":"Massague","year":"2005","journal-title":"Genes Dev"},{"key":"10.1053\/j.jvca.2026.09.050_bib0032","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","article-title":"TGFb signalling in context","volume":"13","author":"Massague","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0033","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/01.RES.0000200180.01710.e6","article-title":"Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: Implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension","volume":"98","author":"Teichert-Kuliszewska","year":"2006","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.09.050_bib0034","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cmet.2015.03.010","article-title":"BMPR2 preserves mitochondria function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension","volume":"21","author":"Diebold","year":"2015","journal-title":"Cell Metab"},{"key":"10.1053\/j.jvca.2026.09.050_bib0035","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/hc3201.094152","article-title":"Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins","volume":"104","author":"Morrell","year":"2001","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.09.050_bib0036","doi-asserted-by":"crossref","first-page":"L1059","DOI":"10.1152\/ajplung.00180.2006","article-title":"BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells","volume":"291","author":"Lagna","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0037","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0038","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jvca.2026.09.050_bib0039","doi-asserted-by":"crossref","first-page":"eaaz5660","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0040","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1084\/jem.20111741","article-title":"Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension","volume":"211","author":"Sawada","year":"2014","journal-title":"J Exp Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0041","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1038\/s41598-022-11435-x","article-title":"Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension","volume":"12","author":"Joshi","year":"2022","journal-title":"Sci Rep"},{"key":"10.1053\/j.jvca.2026.09.050_bib0042","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1161\/ATVBAHA.117.309696","article-title":"Codependence of bone morphogenetic protein receptor 2 and transforming growth factor-b in elastic fiber assembly and its perturbation in pulmonary arterial hypertension","volume":"37","author":"Tojais","year":"2017","journal-title":"Atherioscler Thromb Vasc Biol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0043","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-025-02287-8","article-title":"Signaling pathways and targeted therapy for pulmonary hypertension","volume":"10","author":"Adu-Amankwaah","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1053\/j.jvca.2026.09.050_bib0044","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.125.323681","article-title":"Activin A-endothelin-1 axis governs pulmonary vascular remodeling: Mechanistic basis for emerging therapies in PAH","volume":"46","author":"Faizah","year":"2026","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0045","doi-asserted-by":"crossref","unstructured":"Jankowski K, Ghosh A, Ochoa MT, et al. Sotatercept reverses SIN3a deficiency-driven PAH by reprogramming BMPR2\/TGF-beta-HIF-1alpha signaling pathways. bioRxiv [online] 2026;2026.02.03.703590.","DOI":"10.64898\/2026.02.03.703590"},{"key":"10.1053\/j.jvca.2026.09.050_bib0046","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/CIRCRESAHA.115.303404","article-title":"The genetics of pulmonary arterial hypertension","volume":"115","author":"Austin","year":"2014","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.09.050_bib0047","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02341-2020","article-title":"Targeting transforming growth factor-beta receptors in pulmonary hypertension","volume":"57","author":"Guignabert","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0048","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/303059","article-title":"Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene","volume":"67","author":"Deng","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1053\/j.jvca.2026.09.050_bib0049","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMP2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"Lane","year":"2000","journal-title":"Nat Genet"},{"key":"10.1053\/j.jvca.2026.09.050_bib0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200108023450502","article-title":"Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred","volume":"345","author":"Newman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0051","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.RES.0000166926.54293.68","article-title":"Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension","volume":"96","author":"Yang","year":"2005","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.09.050_bib0052","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/01.CIR.0000012754.72951.3D","article-title":"Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor","volume":"105","author":"Atkinson","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.09.050_bib0053","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1183\/09031936.02.01762002","article-title":"BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives","volume":"20","author":"Humbert","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0054","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1164\/rccm.200311-1602OC","article-title":"Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension","volume":"170","author":"Richter","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0055","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.122.061501","article-title":"Serum and pulmonary expression profiles of the activin signaling system in pulmonary arterial hypertension","volume":"147","author":"Guignabert","year":"2023","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.09.050_bib0056","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41467-021-21961-3","article-title":"An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension","volume":"12","author":"Ryanto","year":"2021","journal-title":"Nat Commun"},{"key":"10.1053\/j.jvca.2026.09.050_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1064290","article-title":"Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure","volume":"10","author":"Joshi","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0058","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.tips.2025.04.008","article-title":"Sotatercept in pulmonary arterial hypertension","volume":"46","author":"Cracowski","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1053\/j.jvca.2026.09.050_bib0059","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.tips.2025.05.004","article-title":"Anti-remodeling therapies in pulmonary arterial hypertension","volume":"46","author":"Boucherat","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1053\/j.jvca.2026.09.050_bib0060","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/MCP.0000000000001278","article-title":"Promising signalling pathways for the treatment of pulmonary arterial hypertension","volume":"32","author":"Budhram","year":"2026","journal-title":"Curr Opin Pulm Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2026.1827438","article-title":"RKER-012, a modified ActRIIB-Fc ligand trap with BMP sparing properties, attenuates pathological features of experimental pulmonary arterial hypertension","volume":"13","author":"Babbs","year":"2026","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0062","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0063","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01347-2022","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0064","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01972-2022","article-title":"Sotatercept for pulmonary arterial hypertension: something old and something new","volume":"61","author":"Rubin","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0065","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1164\/rccm.202409-1698OC","article-title":"Consistent safety and efficacy of sotatercept for pulmonary arterial hypertension in BMPR2 mutation carrier and noncarriers: A planned analysis of a phase II, double-blind, placebo-controlled clinical trial (PULSAR)","volume":"211","author":"Montani","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0066","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1164\/rccm.202503-0539ED","article-title":"Simplifying sotatercept in pulmonary arterial hypertension: Genetic context meets treatment response","volume":"211","author":"Maron","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0067","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0068","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1164\/rccm.202208-1547OC","article-title":"Minimal clinically important difference in the 6-minute-walk distance for patients with pulmonary arterial hypertension","volume":"207","author":"Moutchia","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0069","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1093\/cvr\/cvad121","article-title":"Sotatercept as a next-generation therapy for pulmonary arterial hypertension: Insights from the STELLAR trial","volume":"119","author":"Kopec","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2026.09.050_bib0070","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMe2503944","article-title":"Sotatercept and the clinical transformation of pulmonary arterial hypertension","volume":"392","author":"Maron","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0071","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/d41573-024-00054-y","article-title":"FDA approves Merck & Co\u2019s pulmonary arterial hypertension drug sotatercept","volume":"23","author":"Kingwell","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.jvca.2026.09.050_bib0072","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-024-02058-9","article-title":"Sotatercept: First approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2026.09.050_bib0073","first-page":"491","article-title":"The effectiveness and value of sotatecept for pulmonary arterial hypertension: A summary from the Institute for Clinical and Economic Review\u2019s Midwest Comparative Effectiveness Public Advisory Council","volume":"30","author":"Nikitin","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1053\/j.jvca.2026.09.050_bib0074","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/cpt.3116","article-title":"The impact of immunogenicity on the pharmacokinetics, efficacy, and safety of sotatercept in a phase III study of pulmonary arterial hypertension","volume":"115","author":"Liao","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2026.09.050_bib0075","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01107-2023","article-title":"Effects of sotatercept on haemodynamics and right heart function: Analysis of the STELLAR trial","volume":"62","author":"Souza","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0076","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01513-2023","article-title":"Reducing the pressure in pulmonary arterial hypertension: Sotatercept, haemodynamics and the right ventricle","volume":"62","author":"Price","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0077","first-page":"A101","article-title":"Influence of background PAH therapy on the efficacy and safety of sotatercept in patients with PAH: A post hoc analysis of the STELLAR study","volume":"14","author":"Meyer","year":"2024","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0078","first-page":"A081","article-title":"Influence of cardiometabolic comorbidities on the efficacy and safety profile of sotatercept in patients with PAH: A post hoc analysis of the STELLAR study","volume":"14","author":"Kopec","year":"2024","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0079","first-page":"A068","article-title":"Consistency of the efficacy and safety profile of sotatercept across ESC\/ERS risk strata: A post hoc analysis of the STELLAR study","volume":"14","author":"Humbert","year":"2024","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0080","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacasi.2025.12.009","article-title":"Phase 3, open-label multicenter study of sotatercept in Japanese participants with pulmonary arterial hypertension","volume":"6","author":"Matsubara","year":"2026","journal-title":"JACC Asia"},{"key":"10.1053\/j.jvca.2026.09.050_bib0081","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12325-023-02684-x","article-title":"Population health model predicting the long-term impact of sotatercept on morbidity and mortality in patients with pulmonary arterial hypertension (PAH)","volume":"41","author":"McLaughlin","year":"2024","journal-title":"Adv Ther"},{"key":"10.1053\/j.jvca.2026.09.050_bib0082","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1007\/s12325-025-03241-4","article-title":"Long-term mortality and morbidly impact on patients with pulmonary arterial hypertension (PAH) if access to sotatercept is delayed: A simulation model","volume":"42","author":"Alsumali","year":"2025","journal-title":"Adv Ther"},{"key":"10.1053\/j.jvca.2026.09.050_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.134150","article-title":"Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up","volume":"447","author":"Naeem","year":"2026","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0084","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/ph19050760","article-title":"Sotatercept as an add-on to background therapy in idiopathic pulmonary arterial hypertension: Insights from a real-world cohort","volume":"19","author":"Filippatos","year":"2026","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1053\/j.jvca.2026.09.050_bib0085","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01070-2023","article-title":"Effects of sotatercept on lung diffusion capacity and blood gases in patients with pulmonary arterial hypertension","volume":"62","author":"Olsson","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0086","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.3390\/jcm11154568","article-title":"The paradox of pulmonary vascular resistance: Restoration of pulmonary capillary recruitment as a sine qua non for true therapeutic success in pulmonary arterial hypertension","volume":"11","author":"Langleben","year":"2022","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0087","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.healun.2024.11.037","article-title":"Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR","volume":"44","author":"Gomberg-Maitland","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.jvca.2026.09.050_bib0088","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01424-2024","article-title":"Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies","volume":"65","author":"Hoeper","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2026.04.056","article-title":"Sotatercept safety and efficacy in intermediate- to low-risk pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR [online ahead of print]","author":"Gomberg-Maitland","year":"2026","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.09.050_bib0090","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01483-2024","article-title":"Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension","volume":"64","author":"Savale","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0091","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011227","article-title":"SPECTRA phase 2b study: Impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension","volume":"17","author":"Waxman","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2026.09.050_bib0092","unstructured":"Bogaard HJ, Toth EN. Right ventricular compensation with sotatercept: A prospective single arm open label phase 4 study to evaluate the effects of sotatercept on right ventricular function in pulmonary arterial hypertension (RECOMPENSE). 2025. Available at:https:\/\/clinicaltrials.gov\/search?cond=nct06658522&viewType=Card. Accessed August 19, 2026."},{"key":"10.1053\/j.jvca.2026.09.050_bib0093","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01435-2024","article-title":"A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: Interim results of SOTERIA","volume":"66","author":"Preston","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0094","doi-asserted-by":"crossref","first-page":"A4981","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A4981","article-title":"Long-term safety and exposure-adjusted incidence rates of adverse events from pooled sotatercept studies (PULSAR, SPECTRA, STELLAR, and SOTERIA)","volume":"211","author":"Preston","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0095","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0096","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.09.050_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100750","article-title":"Reaching for the summit in pulmonary arterial hypertension with sotatercept: Results of the ZENITH study","volume":"6","author":"Condliffe","year":"2025","journal-title":"Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0098","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa2508170","article-title":"Sotatercept for pulmonary arterial hypertension within the first year after diagnosis","volume":"393","author":"McLaughlin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0099","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/psp4.13166","article-title":"Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension","volume":"13","author":"Ait-Oudhia","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0100","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/cpt.3524","article-title":"Population pharmacokinetic\/pharmacodynamic and exposure-response modeling analyses of sotatercept in healthy participants and patients with pulmonary arterial hypertension","volume":"117","author":"Ait-Oudhia","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2026.09.050_bib0101","article-title":"Case report: Use of sotatercept to treat pulmonary arterial hypertension in a patients with congenital hemorrhagic telangiectasia","volume":"58","author":"Ramakrishnan","year":"2025","journal-title":"Respir Med Case Rep"},{"key":"10.1053\/j.jvca.2026.09.050_bib0102","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70239","article-title":"Sotatercept in pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: A case series and systematic review","volume":"16","author":"Chillingarashvili","year":"2026","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0103","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s43856-026-01452-6","article-title":"Sotatercept for the treatment of portopulmonary hypertension: A case report","volume":"6","author":"Jose","year":"2026","journal-title":"Commun Med (Lond)"},{"key":"10.1053\/j.jvca.2026.09.050_bib0104","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70276","article-title":"Sotatercept for decompensated pulmonary arterial hypertension requiring VA ECMO: First Canadian ICU experience","volume":"16","author":"Taylor","year":"2026","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2026.100585","article-title":"Sotatercept treatment in a patient with end-stage bronchiolitis obliterans syndrome after lung transplantation","volume":"13","author":"Poor","year":"2026","journal-title":"JHLT Open"},{"key":"10.1053\/j.jvca.2026.09.050_bib0106","article-title":"Activin signaling inhibitor sotatercept in pulmonary veno-occlusive disease: Building a bridge to transplantation?","volume":"62","author":"Mietzner","year":"2026","journal-title":"Respir Med Case Rep"},{"key":"10.1053\/j.jvca.2026.09.050_bib0107","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17476348.2025.2581340","article-title":"Treatment options for children with pulmonary arterial hypertension associated with congenital heart disease","volume":"20","author":"Wacker","year":"2026","journal-title":"Expert Rev Respir Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0108","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000001239","article-title":"Updates in the treatment of pediatric pulmonary arterial hypertension [online ahead of print]","author":"Jafri","year":"2026","journal-title":"Cardiol Rev"},{"key":"10.1053\/j.jvca.2026.09.050_bib0109","doi-asserted-by":"crossref","DOI":"10.1007\/s00246-026-04349-2","article-title":"Off-label sotatercept use in pediatric pulmonary hypertension: A single-center retrospective hemodynamic study [online ahead of print]","author":"Rao","year":"2026","journal-title":"Pediatr Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0110","unstructured":"Merck Sharp & Dohme. Study to evaluate sotatercept (MK-7962) in children with pulmonary arterial hypertension (PAH) (MK-7962-008) (MOONBEAM). 2026. Available at: https:\/\/clinicaltrials.gov\/search?cond=nct05587712&viewType=Card. Accessed August 19, 2026."},{"key":"10.1053\/j.jvca.2026.09.050_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaccas.2026.108814","article-title":"Sotatercept in congenital heart disease-associated pulmonary arterial hypertension and Eisenmenger syndrome: First case series","author":"Leung","year":"2026","journal-title":"JACC Case Rep"},{"key":"10.1053\/j.jvca.2026.09.050_bib0112","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70283","article-title":"Sotatercept in patients with Eisenmenger syndrome","volume":"16","author":"Tutarel","year":"2026","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0113","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-113430","volume":"16","author":"Yoshida","year":"2026","journal-title":"BMJ Open"},{"key":"10.1053\/j.jvca.2026.09.050_bib0114","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.3390\/jcm14155177","article-title":"Sotatercept for connective tissue disease-associated pulmonary arterial hypertension with concomitant interstitial lung disease: Efficacy and safety insights","volume":"14","author":"Dagher","year":"2025","journal-title":"J Clin Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0115","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1079","article-title":"Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of sotatercept in the management of pulmonary hypertension","volume":"11","author":"Hadi","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"10.1053\/j.jvca.2026.09.050_bib0116","article-title":"Real-world performance of sotatercept in PAH patients with cardiopulmonary comorbidities: A retrospective single center experience","volume":"15","author":"Rojas","year":"2025","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0117","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.chest.2025.12.004","article-title":"Association between sotatercept and improved lung function in sarcodosis-associated pulmonary hypertension","volume":"169","author":"Poor","year":"2026","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.09.050_bib0118","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02731-2025","article-title":"Sotatercept improves small airway disease and hyperinflation in patients with pulmonary hypertension","volume":"67","author":"Poor","year":"2026","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0119","article-title":"Sotatercept blunts ventilatory drive to carbon dioxide with improved exertional dyspnea in pulmonary arterial hypertension","volume":"68","author":"Reddy","year":"2026","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0120","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00064-2025","article-title":"Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension","volume":"65","author":"Olsson","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0121","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70160","article-title":"Sotatercept to wean off prostacyclin infusion therapy for pulmonary hypertension: A case report","volume":"15","author":"Strick","year":"2025","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0122","doi-asserted-by":"crossref","DOI":"10.1111\/crj.70149","article-title":"Use of sotatercept to facilitate transition from intravenous to oral prostacyclin therapy","volume":"19","author":"Dagher","year":"2025","journal-title":"Clin Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0123","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ajrccm\/aamag147","article-title":"Sotatercept and prostacyclin de-escalation in stable pulmonary arterial hypertension: A single-centre case series","volume":"212","author":"Moles","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2026.06.021","article-title":"De-escalation of prostacyclin-based therapy in patients treated with sotatercept [online ahead of print]","author":"Tasevac","year":"2026","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.09.050_bib0125","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.healun.2026.05.028","article-title":"Haemodynamic responses to sotatercept and parenteral prostacyclins in pulmonary arterial hypertension patients","volume":"45","author":"Genecand","year":"2026","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.jvca.2026.09.050_bib0126","article-title":"Pathophysiology and prevalence of high output heart failure in group 1 pulmonary hypertension","volume":"67","author":"Reddy","year":"2026","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0127","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.125.076913","article-title":"Acute hemodynamic effects of sotatercept","volume":"152","author":"Kremer","year":"2025","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.09.050_bib0128","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/ehf2.14833","article-title":"Precision cardiac monitoring: Algorithmic real-time assessment of right ventricular function in pulmonary hypertension","volume":"11","author":"Kremer","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.jvca.2026.09.050_bib0129","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.healun.2025.07.032","article-title":"Hemodynamic effects of sotatercept administration in pulmonary hypertension\u2014Insights from remote monitoring","volume":"44","author":"Nagaraj","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.jvca.2026.09.050_bib0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2026.02.5103","article-title":"Sotatercept in pulmonary arterial hypertension: Central, hematologic, and peripheral mechanisms of benefit","volume":"88","author":"Reddy","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0131","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.jacc.2022.02.050","article-title":"Venous tone and stressed blood volume in heart failure: JACC review topic of the week","volume":"79","author":"Fudim","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0132","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jacc.2026.03.049","article-title":"From clinical success to physiologic understanding: Disentangling sotatercept\u2019s effects in PAH","volume":"88","author":"Cascino","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0133","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2025.107520","article-title":"Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials","volume":"160","author":"Abdulelah","year":"2025","journal-title":"Vascul Pharmacol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0134","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/17476348.2025.2530201","article-title":"Efficacy and safety of sotatercept in pulmonary arterial hypertension: A meta-analysis of randomized controlled trials","volume":"19","author":"Ershed","year":"2025","journal-title":"Expert Rev Respir Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0135","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ihj.2026.01.005","article-title":"Efficacy and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized clinical trials","volume":"78","author":"Mantoo","year":"2026","journal-title":"Indian Heart J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0136","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2016.09.942","article-title":"Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension","volume":"68","author":"Assad","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0137","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1093\/eurheartj\/ehac184","article-title":"Pulmonary vascular disease in pulmonary hypertension due to left heart disease: Pathophysiological implications","volume":"43","author":"Omote","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0138","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jacc.2026.01.024","article-title":"Pulmonary hypertension associated with left heart disease: Challenges, emerging strategies, and future directions","volume":"88","author":"Khan","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0139","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01344-2024","article-title":"Pulmonary hypertension associated with left heart disease","volume":"64","author":"Maron","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0140","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","article-title":"Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: A retrospective cohort study","volume":"8","author":"Maron","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0141","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2026.06.018","article-title":"Management of heart failure with preserved ejection fraction: 2026 ACC expert consensus decision pathway: A report of the American College of Cardiology Solution Set Oversight Committee [online ahead of print]","author":"Kittleson","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0142","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.126.080191","article-title":"Stepping into a new era: Sotatercept for the treatment of combined precapillary and postcapillary pulmonary hypertension from heart failure with preserved ejection fraction","volume":"153","author":"Sarma","year":"2026","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.09.050_bib0143","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/CIRCULATIONAHA.126.079918","article-title":"Sotatercept for combined post- and precapillary pulmonary hypertension associated with heart failure: Results from the phase 2, randomized, placebo-controlled CADENCE study","volume":"153","author":"Gomberg-Maitland","year":"2026","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.09.050_bib0144","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s10741-026-10652-0","article-title":"Beyond vasodilation: Sotatercept and the remodeling hypothesis in HFpEF-associated pulmonary hypertension","volume":"31","author":"Sperry","year":"2026","journal-title":"Heart Fail Rev"},{"key":"10.1053\/j.jvca.2026.09.050_bib0146","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12012-025-10088-2","article-title":"Pharmacovigilance analysis of sotatercept for treatment of pulmonary arterial hypertension based on the FAERS database","volume":"26","author":"Zhang","year":"2026","journal-title":"Cardiovasc Toxicol"},{"key":"10.1053\/j.jvca.2026.09.050_bib0147","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1164\/rccm.202501-0056RL","article-title":"Development of new intrapulmonary shunts in pulmonary arterial hypertension patients treated with sotatercept","volume":"211","author":"Mitchell","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0148","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1164\/rccm.202502-0344RL","article-title":"Severe hypoxemia and pulmonary capillary dilatations in pulmonary arterial hypertension patients treated with sotatercept","volume":"211","author":"Olsson","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.09.050_bib0149","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00768-2025","article-title":"Pericardial effusion in sotatercept phase 3 trials: Insights from STELLAR and ZENITH","volume":"66","author":"Hoeper","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0150","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.chest.2025.07.4083","article-title":"Sotatercept and the development of pericardial effusions: An emerging safety signal","volume":"169","author":"Larson","year":"2026","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.09.050_bib0151","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01040-2025","article-title":"Pericardial effusions and sotatercept therapy in pulmonary arterial hypertension: A multicentre, real-world experience","volume":"66","author":"Sahay","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1053\/j.jvca.2026.09.050_bib0152","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70162","article-title":"A case series: Pericardial effusion in patients treated with sotatercept","volume":"15","author":"McKenna","year":"2025","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0153","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70141","article-title":"Pericardial effusion and prostacyclin analog toxicity after initiation of sotatercept","volume":"15","author":"Tager","year":"2025","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0154","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70215","article-title":"Progressive pericardial effusions (PEF) in patients with pulmonary arterial hypertension (PAH) taking sotatercept-association with pre-existing pericardial effusion","volume":"15","author":"Subba","year":"2025","journal-title":"Pulm Circ"},{"key":"10.1053\/j.jvca.2026.09.050_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocmr.2026.102714","article-title":"Sotatercept improves right ventricular function but is associated with new or worsening pericardial effusions: A cardiovascular magnetic resonance study in intermediate-high risk pulmonary arterial hypertension","volume":"28","author":"Virsinskaite","year":"2026","journal-title":"J Cardiovasc Magn Reson"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077026009663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077026009663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:53:08Z","timestamp":1792720388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077026009663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":154,"alternative-id":["S1053077026009663"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2026.09.050","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy. XI: Sotatercept in Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2026.09.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}